Clinical Trial

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

Study acronym: Eluminate-5
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Trial Details
NCT Number NCT07662109
Lead Sponsor AstraZeneca
Conditions Type 2 Diabetes Mellitus
Enrollment 2,000 participants
Start Date 2026-07-06
Primary Completion 2028-07-05 (estimated)
Study Completion 2028-07-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-23